{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:49:17Z","timestamp":1760316557160,"version":"build-2065373602"},"reference-count":45,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2009,8,25]],"date-time":"2009-08-25T00:00:00Z","timestamp":1251158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Oncogenic AKT\/mammalian target of rapamycin (mTOR) signaling has recently been shown to contribute to tumor survival and proliferation in mantle cell lymphoma (MCL) through its downstream effector eukaryotic initiation factor 4E (eIF4E), which may control cyclin D1 protein levels. However, the clinical significance of eIF4E expression in MCL is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The authors investigated the prognostic significance of eIF4E expression in 70 MCL patients uniformly treated with hyper\u2010CVAD and rituximab, alternating with the rituximab, high\u2010dose methotrexate, and cytarabine regimen (R\u2010hyper\u2010CVAD). eIF4E expression was assessed using tissue biopsy specimens obtained before treatment, immunohistochemical methods, and a highly specific monoclonal antibody. Failure\u2010free (FFS) and overall (OS) survival were used as endpoints in univariate and multivariate survival analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>High eIF4E expression was found in 28 (40%) MCL tumors. After a median follow\u2010up of 51 months for survivors, the 5\u2010year FFS was 20.6% for patients with high eIF4E expression, compared with 63.5% for patients with low or no eIF4E expression (<jats:italic>P<\/jats:italic> = .01, log\u2010rank). Similarly, the 5\u2010year OS was 40.1% for patients with high eIF4E expression, compared with 73.8% for patients with low or no eIF4E expression (<jats:italic>P<\/jats:italic> = .018, log\u2010rank). In multivariate analysis, eIF4E expression was associated with poorer FFS and OS, along with age &gt;60 years and high \u03b2<jats:sub>2<\/jats:sub>\u2013microglobulin in the final prognostic model.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>In summary, eIF4E, which seems to recapitulate most of the biologic effects of mTOR signaling in MCL, is an independent predictor of clinical outcome in MCL patients uniformly treated with the R\u2010hyper\u2010CVAD regimen. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24506","type":"journal-article","created":{"date-parts":[[2009,8,25]],"date-time":"2009-08-25T08:52:32Z","timestamp":1251190352000},"page":"4727-4736","source":"Crossref","is-referenced-by-count":16,"title":["Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper\u2010CVAD and rituximab, alternating with rituximab, high\u2010dose methotrexate, and cytarabine"],"prefix":"10.1002","volume":"115","author":[{"given":"Kedar V.","family":"Inamdar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Drakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald J.","family":"Knoblock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Leventaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George Z.","family":"Rassidakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,10,5]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"230","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours","author":"Delsol G","year":"2001"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.21.9638"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.10.2086.2086"},{"key":"e_1_2_6_5_2","first-page":"5541s","article-title":"Characterization of chromosome 11 translocation breakpoints at the bcl\u20101 and PRAD1 loci in centrocytic lymphoma","volume":"52","author":"Williams ME","year":"1992","journal-title":"Cancer Res."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2067"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.s.005"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209886"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"},{"key":"e_1_2_6_12_2","first-page":"1433","article-title":"Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells","volume":"90","author":"Hipp S","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404471"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1212704"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2005.09.009"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.03.029"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106148"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc839"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.13.12.7358"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature02369"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1042"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0419"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65118-8"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3018"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06488.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06655.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015586"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.051078"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/315340a0"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.019"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1309\/JQMR-323G-71Y9-M7MB"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.1.272"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201216"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2909"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-231"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22195"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20037"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.8.2892.2892"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.2.619"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63140-9"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403387"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05716.x"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24506","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:48:26Z","timestamp":1760287706000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,5]]},"references-count":45,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2009,10,15]]}},"alternative-id":["10.1002\/cncr.24506"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24506","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2009,10,5]]}}}